PCI Biotech Holding ASA (LTS:0JGL) Research & Development: kr17.34 Mil (TTM As of Jun. 2025)


What is PCI Biotech Holding ASA Research & Development?

PCI Biotech Holding ASA LTS:0JGL Research & Development is kr17.34 Mil as of Jun. 2025. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PCI Biotech Holding ASA's Research & Development for the six months ended in Jun. 2025 was kr8.39 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was kr17.34 Mil.

PCI Biotech Holding ASA  (LTS:0JGL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PCI Biotech Holding ASA Research & Development Related Terms

PCI Biotech Holding ASA Research & Development Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Research & Development Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.57 71.71 44.76 15.63 16.06

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.79 7.84 7.12 8.94 8.39

PCI Biotech Holding ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr17.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr17.34 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Research & Development of kr17.34 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Research & Development too high?
PCI Biotech Holding ASA's current Research & Development is kr17.34 Mil.
How does PCI Biotech Holding ASA's Research & Development compare to VRTX and REGN?
PCI Biotech Holding ASA's Research & Development of kr17.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Research & Development is kr17.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Research & Development of kr17.34 Mil. The current Research & Development is kr17.34 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Research & Development is kr17.34 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.